Waltham, MA, United States of America

David Freeman

This inventor holds 2 USPTO granted patents and 1 published patent application. Top assignee: Kronos Bio, Inc.. Active years: 2021-2023.

IDiyas Innovation Intelligence. (2026). Inventor Profile: David Freeman. Retrieved from https://idiyas.com/inventor/david-freeman-c17ucfqb

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 2 

% Patents Active = 100.0

Average Co-Inventor Count = 4.0

ph-index = 1


Company Filing History:


Years Active: 2021-2023

Loading Chart...
2 patents (USPTO):Explore Patents

Title: The Innovations of David Freeman

Introduction

David Freeman is an accomplished inventor based in Waltham, MA (US). He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that modulate CDK9 activity. With a total of 2 patents to his name, Freeman's work is paving the way for advancements in cancer treatment.

Latest Patents

Freeman's latest patents focus on substituted pyrazolo[1,5-a]pyrimidines, which serve as inhibitors of CDK9. These compounds are designed to modulate CDK9 activity and are represented by a specific formula. The innovative nature of these inhibitors highlights Freeman's commitment to addressing critical challenges in medical science.

Career Highlights

Freeman is currently employed at Kronos Bio, Inc., where he continues to push the boundaries of drug discovery and development. His expertise in medicinal chemistry and pharmacology has positioned him as a key player in the industry.

Collaborations

Freeman collaborates with notable colleagues, including Peter Mikochik and Joseph P. Vacca. Their combined efforts contribute to the advancement of research and innovation within their field.

Conclusion

David Freeman's work exemplifies the spirit of innovation in the pharmaceutical industry. His contributions are not only significant in terms of patents but also in their potential impact on cancer therapies.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…